Compass Pathways Reports Positive Six-Month Phase 3 Results for Psilocybin Therapy in Treatment-Resistant Depression
Compass Pathways has reported positive six-month results from its second Phase 3 clinical trial evaluating COMP360 psilocybin treatment for treatment-resistant ...
